Monimus Capital Management LP Buys Shares of 364,306 CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Monimus Capital Management LP purchased a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 364,306 shares of the biotechnology company’s stock, valued at approximately $375,000. Monimus Capital Management LP owned approximately 0.47% of CytomX Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the stock. US Bancorp DE purchased a new position in CytomX Therapeutics during the third quarter worth about $40,000. Connor Clark & Lunn Investment Management Ltd. raised its position in CytomX Therapeutics by 10.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 26,373 shares during the last quarter. FMR LLC raised its position in shares of CytomX Therapeutics by 17.3% in the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after acquiring an additional 41,949 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of CytomX Therapeutics by 1.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 16,359 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after acquiring an additional 34,032 shares in the last quarter. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CTMX has been the topic of several recent research reports. StockNews.com upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, March 10th. Wedbush reissued an “outperform” rating and set a $5.00 price target on shares of CytomX Therapeutics in a report on Friday, March 7th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.02.

CytomX Therapeutics Trading Up 10.0 %

NASDAQ CTMX opened at $0.65 on Friday. The firm’s fifty day simple moving average is $0.80 and its two-hundred day simple moving average is $1.00. CytomX Therapeutics, Inc. has a 12-month low of $0.56 and a 12-month high of $5.85. The firm has a market capitalization of $52.03 million, a P/E ratio of 3.82 and a beta of 1.05.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. The firm had revenue of $38.09 million for the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. As a group, sell-side analysts predict that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.